Satellos Bioscience Inc. Common Stock Asset Resilience Ratio
Satellos Bioscience Inc. Common Stock asset resilience ratio. Satellos Bioscience Inc. Common Stock (MSLE) has an Asset Resilience Ratio of 82.78% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Satellos Bioscience Inc. Common Stock (MSLE) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Satellos Bioscience Inc. Common Stock (2007–2025)
Asset resilience ratio of Satellos Bioscience Inc. Common Stock from 2007 to 2025. This chart shows how Satellos Bioscience Inc. Common Stock's Asset Resilience Ratio has changed over time. Read Satellos Bioscience Inc. Common Stock (MSLE) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Satellos Bioscience Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Satellos Bioscience Inc. Common Stock asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $54.38 Million | 82.78% |
| Total Liquid Assets | $54.38 Million | 82.78% |
Asset Resilience Insights
- Very High Liquidity: Satellos Bioscience Inc. Common Stock maintains exceptional liquid asset reserves at 82.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Satellos Bioscience Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Satellos Bioscience Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Satellos Bioscience Inc. Common Stock Asset Resilience Ratio by Year (2007–2025)
Satellos Bioscience Inc. Common Stock asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Satellos Bioscience Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.15% | $17.91 Million | $31.89 Million | +39.45pp |
| 2024-12-31 | 16.70% | $8.50 Million | $50.88 Million | -22.85pp |
| 2023-12-31 | 39.55% | $17.52 Million | $44.30 Million | +38.66pp |
| 2020-12-31 | 0.89% | $10.07K | $1.13 Million | -25.45pp |
| 2015-12-31 | 26.34% | $1.02 Million | $3.89 Million | -2.11pp |
| 2014-12-31 | 28.45% | $1.93 Million | $6.77 Million | +8.12pp |
| 2013-12-31 | 20.33% | $758.44K | $3.73 Million | -1.60pp |
| 2012-12-31 | 21.93% | $662.25K | $3.02 Million | -14.42pp |
| 2011-12-31 | 36.35% | $1.07 Million | $2.94 Million | -16.22pp |
| 2010-12-31 | 52.57% | $1.42 Million | $2.69 Million | -1.69pp |
| 2009-12-31 | 54.26% | $2.51 Million | $4.63 Million | +52.97pp |
| 2007-12-31 | 1.29% | $42.00K | $3.27 Million | -- |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more